PRT062607,1370261-98-5

PRT062607 acetate 产品活性：PRT062607 (P505-15) acetate 是一种口服有效的 Syk 抑制剂 (IC50: 1 nM)，能够抑制炎症和诱导凋亡 (apoptosis)。PRT062607 acetate 在肿瘤异植小鼠模型中，发挥有效的抗肿瘤活性。 产品来源： www.medchemexpress.cn/prt062607-acetate.html 研究领域：Cell Cycle/DNA Damage | Apoptosis | MAPK/ERK Pathway | Cytoskeleton | Protein Tyrosine Kinase/RTK 作用靶点：FAK | Mixed Lineage Kinase | Pyk2 | Src | Apoptosis | PAK | Syk In Vitro: PRT062607 acetate also has significant activity against multiple kinases, with IC50s of 81 nM (Fgr), 88 nM (MLK1), 123 nM (Yes), 139 nM (Flt3), 166 nM (PAK5), 192 nM (Lyn), 244 nM (cSRC), 249 nM (Lck), 108 nM (Pyk), 415 nM (FAK), 1.05 nM (ZAP-70).PRT062607 acetate (0.01-2 μM; 3 d) inhibits Phosphorylation of ERK(Y204), AKT(S473) and SYK(Y352) in Ramos cells, and inhibition of BLNK Tyr84 phosphorylation.PRT062607 acetate (2 μM; 24 h) in SU-DHL6 cells Induces apoptosis in human whole blood.In human whole blood, P505-15 can effectively inhibit B cell antigen receptor-mediated B cell signaling and activation (IC50: 0.27 and 0.28 μM) and Fc receptor 1-mediated induced basophil degranulation (IC50: 0.15 μM). In Vivo: PRT062607 acetate produced dose-dependent anti-inflammatory activity in two rodent models of rheumatoid arthritis. PRT062607 acetate (15, 30 mg/kg; po; bid; 5 d) causes SYK inhibition in mice and prevents BCR-induced splenomegaly in mice.PRT062607 acetate (15 mg/kg; po ; bid; 5 d) SYK inhibition in mice prevents Ramos tumor formation in mouse xenograft models.PRT062607 acetate (10-20 mg/kg; po; bid) prevents BCR mediated splenomegaly and significantly inhibited NHL tumor growth in xenograft models. 相关产品：Bioactive Compound Library Plus | Apoptosis Compound Library | Cell Cycle/DNA Damage Compound Library | Immunology/Inflammation Compound Library | Kinase Inhibitor Library | MAPK Compound Library | Protein Tyrosine Kinase Compound Library | Anti-Cancer Compound Library | Anti-Aging Compound Library | Reprogramming Compound Library | Oxygen Sensing Compound Library | Cytoskeleton Compound Library | Anti-Pancreatic Cancer Compound Library | Anti-Obesity Compound Library | Angiogenesis-Related Compound Library | Anti-Prostate Cancer Compound Library | Anti-Pulmonary Fibrosis Compound Library | Pain-Related Compound Library | Membrane Protein-targeted Compound Library | Cell Death Library | Serine/Threonine Kinase Inhibitor Library | Multi-Target Compound Library | Bioactive Compound Library Max | MG-132 | Doxorubicin hydrochloride | Bafilomycin A1 | Tamoxifen | Y-27632 | LY294002 | Paclitaxel | Z-VAD-FMK | Acetylcysteine | Angiotensin II human | 2-Deoxy-D-glucose | Staurosporine | Actinomycin D | SB-431542 | 5-Fluorouracil | Bortezomib | Deferoxamine mesylate | Oxaliplatin | Trametinib | Sorafenib | Temozolomide | Gemcitabine | Decitabine | Mdivi-1 | Rotenone | Etoposide | Elesclomol | Ruxolitinib | Monomethyl auristatin E | DAPT